Hanmi Pharmaceutical (South Korea) informed that its global partner Spectrum Pharmaceuticals will be announcing the results of phase 2 clinical trials for poziotinib, a lung cancer treatment currently under development, at the IASLC 19th World Conference on Lung Cancer.
Spectrum Pharmaceuticals, a US biopharmaceutical company, plans to present the results of phase 2 non-small cell lung cancer study using poziotinib, which includes, for the first time, data on the drug’s efficacy for patients with EGFR and HER2 exon 20 mutations.
Spectrum Pharmaceuticals said it plans to share updated data on the study during an oral presentation at the lung cancer academic conference in Toronto, Canada, on Sept. 24.
Looking ahead, Spectrum Pharmaceuticals said it is working to expand the poziotinib clinical program to explore the drug’s efficacy in a number of new areas, including first-line treatment of NSCLC, treatment of other solid tumors with EGFR or HER2 mutations, as well as other combination therapies.
Founded in 1973 and headquartered in Seoul (South Korea), Hanmi Pharmaceutical has two areas of interest: developing longer-lasting peptide and protein therapeutics using its “Lapscovery” technology, and developing small molecule tyrosine-kinase inhibitors for cancer and autoimmune diseases. Its strategy was to developmental incremental modifications of existing drugs, create new combination drugs, and to develop novel drugs. In February 2015 Hanmi licensed rights in the rest of the world outside of South Korea to Spectrum Pharmaceuticals.